Preview

Tuberculosis and Lung Diseases

Advanced search

CALCULATION OF CLINICAL AND ECONOMIC EFFICIENCY OF PROCEDURE OF ETIOLOGICAL DIAGNOSTICS OF TUBERCULOSIS

https://doi.org/10.21292/2075-1230-2017-95-5-65-71

Abstract

The article describes clinical (respective time of obtaining data on drug resistance) and economic (respective costs of reagents and consumables) efficiency of various procedures for etiological diagnostics of tuberculosis and prescription of chemotherapy regimens. The procedure developed and accepted by Ural Phthisiopulmonology Research Institute has been offered. According to this procedure costs of reagents and consumables when testing drug susceptibility to first and second line drugs for the patients with positive sputum tests makes about 5,000 RUR, time required for obtaining the results is 48 hours since delivery of the specimen to laboratory, time for confirmation of drug susceptibility pattern by culture is 30-40 days. For the patients with scanty bacillary excretion costs of reagents and consumables when testing drug susceptibility to first and second line drugs makes about 6,000 RUR, time required for obtaining the results is 8-14 days since delivery of the specimen to laboratory, time for confirmation of drug susceptibility profile by culture is 30-40 days. Additionally to development of rational testing procedures, the main ways to enhance efficiency of etiological diagnostics are to stop double testing, exclude excessive and non-diagnostics tests, thoroughly reject low quality specimens delivered to laboratory.

 

About the Authors

D. V. Vаkhrushevа
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Candidate of Biological Sciences, Academic Sectretary


S. N. Skornyakov
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Doctor of Medical Sciences, Professor, Director


N. I. Eremeevа
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Candidate of Biological Sciences, Senior Researcher


T. V. Umpelevа
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Candidate of Biological Sciences, Senior Researcher


K. V. Belousovа
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Candidate of Biological Sciences, Senior Researcher


M. A. Krаvchenko
Ural Phthisiopulmonology Research Institute, Yekaterinburg
Russian Federation
Candidate of Biological Sciences, Head of Laboratory


References

1. Balabanova Ya.M., Drobnievskiy F., Fedorin I.M. et al. Optimization of laboratory diagnostics of tuberculosis using modern bacteriological and molecular genetic techniques. Tuberculosis and Lung Diseases, 2011, vol. 88, no. 2, pp. 36-43. (In Russ.)

2. Vasilieva I.A. Strategiya razvitiya ftiziatrii i perspektivnye napravleniya nauchnykh issledovaniy v Rossiyskoy Federatsii. [Strategy for tuberculosis control development and promising fields of research in the Russian Federation]. Website of the Russian Phthisiologists' Society. Available at http://xn--80ajxnaj3eq.xn--p1ai/upload/events/nov-2016/presentation.pdf

3. Medical laboratories. Certain requirements to quality and competency. GOST R ISO 15189-2009. (In Russ.)

4. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya. [Federal recommendations for diagnostics and treatment of respiratory tuberculosis in children]. Moscow, Tver, Triada Publ., 2014, 56 p.

5. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple drug resistance]. Moscow, Tver, Triada Publ., 2014, 72 p.

6. Federal'nye klinicheskie rekomendatsii po organizatsii i provedeniyu mikrobiologicheskoy i molekulyarno-geneticheskoy diagnostiki tuberkuleza. [Federal clinical recommendations in organisation and implementation of microbiological and molecular-genetic diagnostics of tuberculosis]. Moscow, 2015, 35 p.

7. Dighe A., Makar R., Lewandrowski K. Medicolegal liability in laboratory medicine. Semin. Diagn. Pathol., 2007, vol. 24, no. 2, pp. 98-107.

8. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva, WHO, 2008 (WHO/HTM/TB/2008.392).

9. Zhang Y., Permar S., Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Mol. Microbiol., 2002, vol. 51, pp. 42-49.


Review

For citations:


Vаkhrushevа D.V., Skornyakov S.N., Eremeevа N.I., Umpelevа T.V., Belousovа K.V., Krаvchenko M.A. CALCULATION OF CLINICAL AND ECONOMIC EFFICIENCY OF PROCEDURE OF ETIOLOGICAL DIAGNOSTICS OF TUBERCULOSIS. Tuberculosis and Lung Diseases. 2017;95(5):65-71. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-5-65-71

Views: 976


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-1230 (Print)
ISSN 2542-1506 (Online)